Study of Brentuximab Vedotin (SGN-35) in Pediatric Participants With Relapsed or Refractory (r/r) Systemic Anaplastic Large-Cell Lymphoma or Hodgkin Lymphoma

NCT01492088 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

36

Enrollment

INDUSTRY

Sponsor class

Conditions

Relapsed or Refractory Hodgkin Lymphoma
Relapsed or Refractory Anaplastic Large-cell Lymphoma

Interventions

DRUG: Brentuximab vedotin

Sponsor

Millennium Pharmaceuticals, Inc.